-+ 0.00%
-+ 0.00%
-+ 0.00%

Ganli Pharmaceutical announced that Ganli Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, recently received the GZC8072 “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials for weight control indications. This product is a class 1 biological product for therapeutic use. As of March 31, 2026, the total R&D cost of the project was RMB 469.553 million.

Zhitongcaijing·08/24/2026 09:09:02
Listen to the news
Ganli Pharmaceutical announced that Ganli Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, recently received the GZC8072 “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials for weight control indications. This product is a class 1 biological product for therapeutic use. As of March 31, 2026, the total R&D cost of the project was RMB 469.553 million.